The information presented in Oncology News Connection (ONC) eNewsletter is provided for physicians and other healthcare providers only and should not be shared with any current or future patients. If you are not a healthcare provider, we welcome you to sign up for Thrive eNewsletter to receive the latest information and blog highlights from Fox Chase Cancer Center.
Fox Chase Cancer Center and Temple Health are pleased to announce the new Fox Chase-Temple Urologic Institute, a groundbreaking initiative that will concentrate on both benign and oncologic urology. With over 30 providers, the Institute will provide services at multiple locations throughout the greater Philadelphia area.
“Our urologists have experience treating some of the most complex and advanced oncologic and benign urologic conditions. As leaders in the field, our urologists not only stay on top of the latest changes in medicine but often lead the development of new treatment advances and surgical techniques,” said Robert Uzzo, MD, MBA, FACS, President and CEO of Fox Chase Cancer Center and Executive Director of the Institute. The new Institute’s executive management team includes Alexander Kutikov, MD, FACS; Jack Mydlo, MD, MBA, Daniel Eun, MD; and Jay Simhan, MD, FACS.
at AUA 2023 after the announcement of the new Fox Chase-Temple Urologic Institute
Beyond general urologic care, the highly experienced benign urology team specializes in less common procedures such as advanced perineal and abdominal reconstruction, prostate enucleation, bladder augmentation and urinary diversion, complex bladder pathology, and vaginal reconstruction.
The Fox Chase-Temple Urologic Institute will offer patients access to cutting-edge clinical trials, targeted therapies, immunotherapies, and advanced radiation therapies for the treatment of urologic cancers. Its urologic oncologists will collaborate closely with renowned medical and radiation oncologists to take a multidisciplinary approach to treating cancer, including diagnosis, treatment, and follow-up care.
Meeting biweekly to discuss patient cases and potential treatment options, the Institute’s team will leverage their extensive experience as one of the largest fellowship-trained genitourinary cancer teams in the country.
The Fox Chase-Temple Urologic Institute is designed to provide a seamless transition for patients with urologic cancers who require treatment for benign urology conditions following cancer therapy. These services, as well as many others, will be offered at multiple locations.
Outpatient Offices:
- Fox Chase – Buckingham
- Fox Chase – East Norriton
- Fox Chase – Huntingdon Pike
- Temple University Hospital – Main Campus
- Temple Health – Center City
- Temple Health – Chestnut Hill Hospital
- Temple Health – Fort Washington
- Temple Health – Suburban
Surgical and Inpatient Facilities:
- Temple University Hospital – Main Campus
- Fox Chase – Main Campus
- Temple University Hospital – Jeanes Campus
- Temple Health – Chestnut Hill Hospital
There are ongoing plans to add providers and expand as the Institute grows.
“With the creation of this new urologic institute, Temple Health and Fox Chase will now be able to extend our exceptional, cutting-edge care to patients closer to their homes,” said Uzzo. “We are thrilled to extend these services to our neighboring communities and are committed to providing our patients with the quality and convenience they deserve from their healthcare providers.”